Archie Goodburn, a 24-year-old British swimmer living with a rare and inoperable form of brain cancer, is making a passionate plea for increased government support for those affected by the disease. Despite a breakthrough treatment that has allowed him to resume competition, Goodburn argues that the lack of advancements in drug development is unacceptable, with only one new medication introduced in the last two decades. As he prepares to compete in the upcoming Commonwealth Games in Glasgow, he is determined to advocate for change in the healthcare system that has long neglected brain cancer research.
A Life Altered
Goodburn’s journey took a dramatic turn two years ago when he began experiencing troubling symptoms during training sessions. Initially dismissed as fatigue, these episodes escalated to severe weakness, numbness on his left side, and overwhelming feelings of fear and nausea. The turning point came in April 2024, when he narrowly missed qualifying for the Olympics, leading to the discovery of three oligodendrogliomas—tumours that constitute about 3% of all brain cancer cases.
The introduction of Vorasidenib, a revolutionary treatment, offered Goodburn a lifeline, delaying the need for chemotherapy and radiotherapy that could have severely impacted his cognitive abilities and disrupted both his swimming career and his studies in chemical engineering. “Vorasidenib only bought me four years, according to the trials. I need more,” he insists, vowing to keep campaigning for better support until his last breath.
The Funding Crisis
Brain cancer remains the leading cause of cancer-related deaths among children and adults under 40. Alarmingly, since 2002, it has received a mere 1% of the UK government’s national cancer research budget. Goodburn and experts highlight a significant “translational gap” in the research process, where promising early-stage discoveries struggle to secure funding for clinical trials.
The all-party parliamentary group on brain tumours has dubbed this disconnect the “valley of death,” attributing it to a conservative funding system that often stifles innovation. Even when resources are allocated, regulatory barriers frequently hinder the availability of new treatments. Goodburn points out that only a fraction of the £40 million pledged by the government for brain cancer in 2018 has been utilised effectively since then.
A Call to Action
Goodburn, alongside the Brain Cancer Justice campaign, is urging the government to expedite the release of the remaining funds and ensure they are directed towards frontline researchers. They are advocating for the appointment of a dedicated brain cancer lead within the government, increased genome sequencing for patients at diagnosis to broaden access to clinical trials, and the establishment of a “right to try” policy for potentially life-saving treatments.
In response to public pressure, the Department of Health and Social Care has acknowledged the need for enhanced research into brain tumours and is committed to improving patient access to innovative medications. However, many remain sceptical about the pace of change.
Goodburn’s battle is not solely personal; he sees his advocacy work as essential in addressing the disparities in healthcare. “I campaign because of the disparity in care, the lack of funding, but also because I believe that my campaigning can actually make a difference to my own future,” he explains.
As he prepares for his event at the Commonwealth Games, Goodburn reflects on the significance of this moment. Competing in Glasgow, where he was inspired by the 2014 Games as a child, is a dream come true. Yet, it is his parallel fight for better treatment options that fuels his resolve.
Why it Matters
Archie Goodburn’s story underscores a critical issue in healthcare: the urgent need for increased investment in brain cancer research. With only a fraction of funding directed towards this devastating disease, the voices of patients like Goodburn are vital in pushing for meaningful change. His commitment to advocacy not only highlights the systemic failings in treatment accessibility but also serves as a rallying cry for a society that must do better for those facing life-threatening conditions. As Goodburn continues to advocate for himself and others, his determination may inspire a broader movement for reform in cancer care and funding.